After two neutropenia treatment-related deaths occurred during study accrual, the data monitoring committee recommended granulocyte colony-stimulating factor after docetaxel treatments, which helped reduce the number of grade 3–4 neutropenia adverse events. The gene discussed is CSF3; the disease is neutropenia.